Lenvatinib/Pembrolizumab Yields Greater Clinical Benefit vs

Lenvatinib plus pembrolizumab displayed a superior clinical benefit vs sunitinib irrespective of patient biomarker subtype in advanced clear cell RCC.

Related Keywords

Massachusetts , United States , Boston , Dana Farber Cancer Institute , America , Toni Choueiri , Nancy Kohlberg , Memorial Sloan Kettering Cancer Center , International Metastatic , Database Consortium , Professor Of Medicine At Harvard Medical School , Lank Center , Genitourinary Oncology At Dana Farber Cancer Institute , Genitourinary Oncology , Kidney Cancer Program , Harvard Cancer Center , Nancy Kohlberg Chair , Harvard Medical School , Western Europe , North America ,